Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H. (2019). Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood, 134 (14). S. 1144 - 1154. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV; cohort 1); salvage chemotherapy and BV, with ineligibility for SCT owing to chemorefractory disease (cohort 2); and progression after SCT without BV (cohort 3). With a median follow-up of 27.6 months, the objective response rate (ORR) by blinded independent central review was 71.9% (95% CI, 65.3-77.9), the complete response rate (CRR) was 27.6%, and the partial response (PR) rate was 44.3%. Median duration of response was 16.5months (range, 0.0+ to 27.0+ [+, no progressive disease at last assessment]) in all patients, 22.1months in cohort 1, 11.1 months in cohort 2, and 24.4 months in cohort 3. Median progression-free survival was not reached in all patients with CR: 13.8 months (95% CI, 12.0-22.1) for patients with PR and 10.9 months (95% CI, 5.6-11.1) for patients with stable disease. Median overall survival was not reached in all patients or in any cohort. Treatment-related adverse events (TRAEs) of any grade occurred in 153 (72.9%) patients; grades 3 and 4 occurred in 25 (12.0%) patients; none resulted in death. Results confirmed effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Chen, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zinzani, Pier LuigiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lee, Hun JuUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Armand, PhilippeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Johnson, Nathalie A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brice, PaulineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Radford, JohnUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ribrag, VincentUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Molin, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vassilakopoulos, Theodoros P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tomita, AkihiroUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Tresckow, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Shipp, Margaret A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lin, JianxinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kim, EunheeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nahar, AkashUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Balakumaran, ArunUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Moskowitz, Craig H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-131421
DOI: 10.1182/blood.2019000324
Journal or Publication Title: Blood
Volume: 134
Number: 14
Page Range: S. 1144 - 1154
Date: 2019
Publisher: AMER SOC HEMATOLOGY
Place of Publication: WASHINGTON
ISSN: 1528-0020
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; MULTICOHORT; NIVOLUMAB; FAILUREMultiple languages
HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/13142

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item